Category: FD&C act

8, analysis, analytics, business, cannabidiol, cannabis, cbd, claim, compliance, consumer, cure, Delta, delta-8 THC, delta-8-tetrahydrocannabinol, delta-9 tetrahydrocannabinol, delta-9-THC, Dispensaries & Retail, drug, Edibles & Processing, FD&C act, FDA, Federal, government, growing, illegal, industry, lab, label, laboratories, laboratory, law, legal, legalization, legalize, legislation, letter, license, marijuana, market, marketing, medical, medicine, misbranded, prevent, product, Quality, recreational, regulation, regulations, regulatory, retail, safety, state, test, Testing, thc, treat, unapproved, update, violate, violation, warning

FDA Issues First Warning Letters for Delta-8 THC

FDA Issues First Warning Letters for Delta-8 THC

In an unprecedented move, the U.S. Food & Drug Administration (FDA) has issued warning letters today to companies selling products containing delta-8 […]

action, analysis, analytics, approval, approved, business, Business Analysis, cannabidiol, cannabis, cbd, claim, compliance, Concentrates & Extracts, consumer, Coronavirus, COVID, COVID-19, cultivation, drug, Edibles & Processing, enforcement, extraction, farm bill, FD&C act, FDA, Federal, government, growing, Health, industry, lab, law, legal, legalization, legalize, legislation, letter, license, marijuana, market, medical, medicine, New, product, Product Development, Quality, regulation, regulations, regulatory, research, retail, safety, state, test, Testing, thc, threaten, U.S. Food and Drug Administration, unapproved, unsubstantiated, warning, wellness

FDA Warning Letters: Stop Claiming CBD Prevents COVID

FDA Warning Letters: Stop Claiming CBD Prevents COVID

Once again, the U.S. Food and Drug Administration (FDA) has issued a number of warning letters to companies selling hemp-derived cannabidiol (CBD) […]